Combination of Rituximab and NK Immunotherapy for B Lymphoma
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
B-cell Lymphoma Recurrent
DRUG: Rituximab|BIOLOGICAL: NK immunotherapy
Relief degree evaluated by the RECIST, It will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST), 3 months
Progress free survival (PFS), 1 year|Overall survival (OS), 3 years
By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Rituximab and natural killer (NK) cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).